This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck …

Recurrent or Metastatic Solid Tumors

~Estimated

~$10 – $7,500

Daiichi SankyoNCT06330064

Phase 1

A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metas…

Recurrent or Metastatic Solid Tumors

~Estimated

~$10 – $7,500

Daiichi SankyoNCT07015697